Neurológia pre prax 3/2026

Neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) as biomarkers disease activity and therapeutic response in multiple sclerosis treated with ocrelizumab

Multiple sclerosis is chronic autoimmune disease with very variable interindividual clinical course and response to the treatment. There is an effort to find biomarkers which reflect two basic aspects of immunopathogenesis of multiple sclerosis, i.e. inflammatory activity and neurodegeneration. We have two biomarkers, neurofilament light chains and glial fibrillary acidic protein measured in serum which mirror both processes, i.e. neuroinflammation and neurodegeneration. We will be able to evaluate the drug efficacy, as shown in this report specifically of ocrelizumab in multiple sclerosis and to modify the treatment according to the principles of personalized medicine.

Keywords: biomarkers, neurofilament light chains, glial fibrillary acidic protein, multiple sclerosis, ocrelizumab